Biopharma company Halozyme Therapeutics (HALO) is on a mission to replace IV-drug delivery. It develops subcutaneous devices to make it easier and quicker to inject high-volume drugs into patients. Halozyme Therapeutics CEO Helen Torley joined Bloomberg Open Interest to talk about the technology and gives her outlook on pharma M&A.

Bloomberg videos, provided by MT Newswires